Dimenhydrinate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dimenhydrinate: From Motion Sickness and Central Vertigo to Allergic Urticaria
One-Sentence Summary
Dimenhydrinate was originally used to treat motion sickness and vertigo of central nervous system origin. The TxGNN model predicts it may be effective for allergic urticaria, but currently there are 0 clinical trials and only 1 publication (a pharmacokinetic study in dogs) linked to this direction, so the support is mostly model prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Motion sickness; vertigo of central nervous system origin (from the knowledge graph, as no approved indication text is recorded in the Singapore licences) |
| Predicted New Indication | Allergic urticaria |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L4 (indirect, pharmacokinetic data only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 8 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, dimenhydrinate is a salt of diphenhydramine and 8-chlorotheophylline. Diphenhydramine is a first-generation H1 receptor antagonist with anticholinergic and sedating properties. These properties underlie its use in motion sickness and vertigo.
Allergic urticaria is driven largely by histamine release acting on H1 receptors in the skin. Blocking H1 receptors is therefore a mechanistically plausible approach, which explains the high model score.
However, the case for repurposing is limited. The only linked publication is a pilot pharmacokinetic study in dogs, which shows drug exposure and the effect on histamine-induced wheals, but does not show clinical efficacy in people with urticaria. In addition, second-generation antihistamines are the usual first-line choice for urticaria and are less sedating, so dimenhydrinate has little room to add value.
Other predictions from the model (cold urticaria, nasal cavity disease, common cold, pharyngitis, acute laryngopharyngitis, urticaria, recalcitrant atopic dermatitis, angioedema, atopic IgE responsiveness) rest on model scores only, with no trials and no efficacy literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30779257 | 2019 | Pharmacokinetic study (pilot, in dogs) | Veterinary Dermatology | Compared diphenhydramine blood levels after oral and intravenous diphenhydramine and oral dimenhydrinate in healthy dogs, and looked at the effect on histamine-induced wheal formation. Supports exposure data, not clinical efficacy in human urticaria. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03013P | Dimenate Tablet 50 mg | Tablet | Not recorded |
| SIN03403P | Novomin Tablet 50 mg | Tablet | Not recorded |
| SIN02765P | Dimenhydrinate Tablets 50 mg (Beacons) | Tablet | Not recorded |
| SIN03550P | Novomin Syrup 15 mg/5 ml | Syrup | Not recorded |
| SIN02519P | Apo-Dimenhydrinate Tablet 50 mg | Tablet | Not recorded |
There are 8 valid single-ingredient registrations in total (tablets, syrups and one injection, Votmine 50 mg/ml). The table lists the first 5.
Safety Considerations
- Contraindications / cautions (from the knowledge graph, not label text): The model's knowledge graph links the drug with caution or contraindication in conditions including angle-closure glaucoma, benign prostatic hyperplasia and bladder neck obstruction, pyloric stenosis, peptic ulcer disease, hyperthyroidism, hypertension and coronary artery disease or myocardial infarction, diabetes and hyperglycaemia, liver disease, gallbladder disease, thrombocytopenia and blood coagulation disease, gout, substance abuse/dependence, and others. These should be checked against the official package insert.
- Drug Interactions: 67 interactions were identified. Two are rated Major: potassium chloride and potassium citrate. Many Moderate interactions involve anticholinergic agents (atropine, hyoscyamine, scopolamine, glycopyrronium, dicyclomine, trospium, propantheline and others), as well as opioids and related agents (morphine, loperamide, opium, eluxadoline), nabilone, metoclopramide and prucalopride.
- Misuse potential: One linked paper describes over-the-counter misuse of dimenhydrinate-containing products by adolescents.
Package insert warnings were not available for this report. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism (H1 blockade) is plausible, but the only supporting study is a veterinary pharmacokinetic pilot with no human efficacy data and no registered trials. Well-established, less sedating second-generation antihistamines already serve as first-line therapy in urticaria. The anticholinergic and sedative profile, the many interactions, and the long list of cautioned conditions add further reasons for caution.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Human clinical evidence (trials or comparative studies) of dimenhydrinate or diphenhydramine in urticaria, compared against second-generation antihistamines
- Assessment of whether any approved indication for urticaria would add value beyond existing options in Singapore
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.